0001140361-25-020241.txt : 20250522 0001140361-25-020241.hdr.sgml : 20250522 20250522210037 ACCESSION NUMBER: 0001140361-25-020241 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250520 FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Venker Eric CENTRAL INDEX KEY: 0001801917 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 25979003 MAIL ADDRESS: STREET 1: C/O ROIVANT SCIENCES, INC. STREET 2: 320 WEST 37TH STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 7TH FLOOR, 50 BROADWAY CITY: LONDON NON US STATE TERRITORY: UNITED KINGDOM PROVINCE COUNTRY: X0 ZIP: SW1H 0DB BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 7TH FLOOR, 50 BROADWAY CITY: LONDON NON US STATE TERRITORY: UNITED KINGDOM PROVINCE COUNTRY: X0 ZIP: SW1H 0DB 4 1 form4.xml FORM 4 X0508 4 2025-05-20 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 6TH FLOOR NEW YORK NY 10018 true President & COO true Common Shares 2025-05-20 4 F 0 39148 11.04 D 1077197 D Common Shares 2025-05-20 4 M 0 100000 3.85 A 1177197 D Common Shares 2025-05-20 4 S 0 100000 10.95 D 1077197 D Stock Option (Right to Buy) 3.85 2025-05-20 4 M 0 100000 0 D 2032-04-19 Common Stock 100000 9723923 D Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2025-05-22